Inhibrx, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 78.71 million compared to USD 48.92 million a year ago. Basic loss per share from continuing operations was USD 1.44 compared to USD 1.12 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.11 USD | +0.09% | -0.70% | -10.24% |
May. 31 | Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Biotechnology Select Industry Index | CI |
May. 31 | Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Global BMI Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.24% | 1.79B | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- INBX Stock
- News Inhibrx, Inc.
- Inhibrx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024